ADA 2026 Scientific Sessions Three Weeks Out (June 5-8 New Orleans) — Peptide-Specific Slate Anchored on Retatrutide, AstraZeneca Eleglipron, Mazdutide
The American Diabetes Association 2026 Scientific Sessions opens in New Orleans on June 5 — three weeks out from today's Sunday digest. The peptide-relevant slate includes multiple Eli Lilly retatrutide TRIUMPH program presentations (some of the seven 2026 readouts expected to land at ADA), the Lilly + Indiana Biosciences Research Institute quintuple agonist (GLP-1/GIP/glucagon/amylin/calcitonin) animal-data poster on May 29, AstraZeneca's full Phase 2b VISTA and SOLSTICE data for eleglipron (formerly elecoglipron/AZD5004/ECC5004) after the April 29 topline, Innovent Biologics' mazdutide multi-program presentations (GLORY-2 18.55% weight loss, DREAMS-3 head-to-head vs semaglutide), Boehringer Ingelheim survodutide SYNCHRONIZE-1 full Phase 3 data, and Pfizer berobenatide (MET-097i) VESPER program updates. ADA combined with the May 21 ASCO abstract drop set up a heavy June peptide news cycle.